The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 1,332,797 | 1,595,889 | 1,660,122 | 3,106,416 |
| Dividends and interest on marketable securities held in trust account | - | - | 1,873,780 | 3,674,951 |
| Dividends earned on marketable securities held in trust account | 1,613,958 | 7,306,965 | - | - |
| Prepaid expenses and other current assets | - | - | -87,390 | -91,237 |
| Prepaid expenses | 41,008 | -202,381 | - | - |
| Due to sponsor | -30,000 | -30,000 | -30,000 | -44,762 |
| Accounts payable and accrued expenses | -12,988 | -8,772 | 8,163 | 29,617 |
| Net cash used in operating activities | -305,157 | -117,363 | -88,105 | -402,919 |
| Proceeds from promissory note - related party | 300,000 | 100,000 | 100,000 | - |
| Net cash provided by financing activities | 300,000 | 100,000 | 100,000 | - |
| Net change in cash | -5,157 | -17,363 | 11,895 | -402,919 |
| Cash - beginning of period | 29,787 | 47,150 | 438,174 | - |
| Cash - end of period | 24,630 | 29,787 | 47,150 | - |
Translational Development Acquisition Corp. (TDACW)
Translational Development Acquisition Corp. (TDACW)